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The rapid responses received following the publication of the DAFNE trial reflect the 
controversy surrounding the current inadequate management of Type 1 diabetes. [1] 
While it is true that the approach is not novel (Ullman, 5th Oct; Black, 6th Oct; Reed 
9th Oct; Chaufan, 12th Oct, Cohen, 22nd Oct), it is new to the UK. The biomedical 
benefits of this intensified approach had been known for some time in parts of 
Europe [2,3] but it was unclear whether these could be transferred to a British 
healthcare setting. Furthermore, the impact on quality of life was unknown, as 
psychological outcomes were not measured in the early German work.  
Several rapid response letters, mostly from pump users or their families - have 
suggested that this research was redundant or wasteful because of the clear 
superiority of continuous subcutaneous insulin infusion (CSII) therapy or because 
carbohydrate counting is already practised to enable a free choice of food (Ullman, 
5th Oct; Black, 6th Oct; Reed, 9th Oct; King, 11th Oct). We appreciate the benefits 
of CSII but, although welcome, they are only used by a minority of people with 
diabetes. Expense is certainly an issue for some (Rosu, 6th Oct) but many simply 
dislike the idea of wearing a pump. [4] Consequently, there are few data on the 
effects of providing all comers with the type of education package routinely offered 
to would-be pump users without the pump itself. DAFNE was not designed as a 
replacement for the pump but as an option for people with type 1 diabetes, whatever 
their method of insulin delivery, enabling them to be free to eat what they like when 
they like while maintaining optimal blood glucose control.  
Among people who have not been trained in DAFNE or related approaches, many use 
carbohydrate counting to restrict their diet to match prescribed insulin doses with 
few using it to make major changes in insulin doses to accommodate real dietary 
freedom. Some individuals have, over time, discovered for themselves how to 
achieve dietary freedom with carbohydrate counting and insulin adjustment but there 
is no published evidence that this improves both biomedical and psychological 
outcomes. Furthermore, we are unaware of evidence that this is undertaken widely. 
DAFNE is an approach to managing type 1 diabetes that teaches explicitly the skills 
necessary for insulin adjustment and true dietary freedom.  
We would challenge the view that DAFNE encourages people to abandon healthy 
eating (Hunter, 11th October). DAFNE divorces the decisions about healthy eating 
from decisions about balancing carbohydrate and insulin. It enables people with 
Type1 diabetes to have the same choices as those without diabetes, i.e. to choose to 
eat regularly or to be flexible, and to choose to eat healthily or not.  
We agree that improvements in satisfaction with treatment, well- being and quality 
of life need to be understood in the light of information about the treatment 
previously recommended to these patients (Ehrlich, 4th Oct). Prior to DAFNE, 
patients injected on average 3.5 (sd=1.0) times per day (indicating that most 
followed a basal bolus regimen) rising to 5.3 (sd=0.7) per day after training. We also 
agree that the separation of basal insulin replacement from meal-related insulin 
probably contributes to DAFNE’s success in controlling blood glucose levels 
(Lawrence & Robinson (9th Oct) and Hunter (11th Oct). However, it cannot 
completely explain the specific improvements in dietary freedom or account for the 
widespread and highly significant improvements in overall treatment satisfaction and 
well-being. It is the demonstration of improvements in psychological as well as 
biomedical outcomes (without the patient having to compromise one in favour of the 
other) and the potential for this to become mainstream treatment that makes the 
DAFNE approach novel.  
The DAFNE trial was financed by research grants from Diabetes UK and as Jenkins 
and Nagi (16th Oct) suggest the initial costs of training healthcare professionals to 
deliver courses may be beyond the current budget of most diabetes centres. 
However, an economic analysis based upon data from the DAFNE trial and other 
studies using the Düsseldorf approach (Bagust, personal communication) suggests 
major cost savings per participant (in terms of anticipated reduction in complications 
of diabetes associated with improved blood glucose control) in the longer term. We 
believe that re-designing services around a DAFNE programme would eventually be 
cost saving although these services probably need to include on-going support for 
the patients to maintain biomedical and psychological benefits (Hunter 11th Oct; 
Jenkins & Nagi, 16th Oct; Chantelau 23rd Oct). Much current diabetes care is neither 
effective nor evidence based, so there may be opportunities to redirect resources.  
We appreciate the need to roll out the DAFNE approach and acknowledge concerns 
about provision of an exclusive service in a few centres in the short term (Hunter, 
11th Oct; Jenkins & Nagi, 16th Oct). The Department of Health has already provided 
funding for a further seven UK centres to be trained to provide and evaluate DAFNE. 
A temporary quality gap could arise, but we believe that a gradual, quality assured 
roll-out, which is carefully monitored, will result in a better service for all in the 
longer term. It is a sad fact that many people struggle with diabetes without having 
the skills with which to treat it successfully (Hanscombe, 16th Oct; King 19th Oct) 
and we believe that a DAFNE or similar approach should be available to all adults 
with Type 1 diabetes. Marked benefits might also be expected in children 
(Hanscombe 16th Oct) and adolescents though this remains to be investigated. For 
now, it seems evident that the DAFNE approach offers a step forward in improving 
the quality of health and quality of life for people with diabetes in the UK.  
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